Actualités PharmaTher Holdings Ltd - PHRM | Actions Canadian Securities Exchange

Outils de qualité professionnelle, pour des investisseurs individuels.

PharmaTher Announces Sale of Psilocybin Program

PharmaTher Announces Sale of Psilocybin Program TORONTO, February 17, 2021 -- InvestorsHub NewsWire -- Newscope...

PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA

PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson's...

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine TORONTO...

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain...

PharmaTher Expands Research Partnership with University Health Network For Development of Digital Therapeutics Platform

TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital...

PharmaTher Provides Update on its Psychedelic Pharmaceuticals Programs

TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital...

PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery A...

TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital...

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Novel Use of Psilocybin to Treat Cancer

TORONTO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital...

Prolific Parkinson’s Researcher Dr. Alberto J. Espay Joins Pharmather as Scientific Advisor

TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital...

Pharmather Files for FDA Orphan Drug Designation for Ketamine in Neuropathic Pain

TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital...

Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals

TORONTO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital...

Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson's Disease

TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital...

Pharmather Announces Exclusive License Agreement with the University of Arizona for the Commercialization of Ketamine in the ...

TORONTO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital...

Pharmather Engages Clarus Securities As Capital Markets Advisor

TORONTO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital...

Newscope Capital (d/b/a Pharmather) Announces Listing on the Canadian Securities Exchange

Discovering and developing psychedelic pharmaceuticals to treat disorders of the brain and nervous system...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

PharmaTher Holdings Ltd (PHRM)

Outils de qualité professionnelle, pour des investisseurs individuels.

PHRM Actualités

PharmaTher Announces Sale of Psilocybin Program

PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation

PharmaTher Expands Research Partnership with University Health Network For Development of Digital Therapeutics Platform

PharmaTher Provides Update on its Psychedelic Pharmaceuticals Programs

PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery A...

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Novel Use of Psilocybin to Treat Cancer

Prolific Parkinson’s Researcher Dr. Alberto J. Espay Joins Pharmather as Scientific Advisor

Pharmather Files for FDA Orphan Drug Designation for Ketamine in Neuropathic Pain

Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals

Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson's Disease

Pharmather Announces Exclusive License Agreement with the University of Arizona for the Commercialization of Ketamine in the ...

Pharmather Engages Clarus Securities As Capital Markets Advisor

Newscope Capital (d/b/a Pharmather) Announces Listing on the Canadian Securities Exchange

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

PharmaTher Holdings Ltd (PHRM) Actualités

PharmaTher Holdings Ltd (PHRM)

Outils de qualité professionnelle, pour des investisseurs individuels.

PHRM Actualités

PharmaTher Announces Sale of Psilocybin Program

PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation

PharmaTher Expands Research Partnership with University Health Network For Development of Digital Therapeutics Platform

PharmaTher Provides Update on its Psychedelic Pharmaceuticals Programs

PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery A...

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Novel Use of Psilocybin to Treat Cancer

Prolific Parkinson’s Researcher Dr. Alberto J. Espay Joins Pharmather as Scientific Advisor

Pharmather Files for FDA Orphan Drug Designation for Ketamine in Neuropathic Pain

Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals

Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson's Disease

Pharmather Announces Exclusive License Agreement with the University of Arizona for the Commercialization of Ketamine in the ...

Pharmather Engages Clarus Securities As Capital Markets Advisor

Newscope Capital (d/b/a Pharmather) Announces Listing on the Canadian Securities Exchange

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités